Sun Biomedical (ASX:SBN) has some interesting news on the horizon in the form of an acquisition, along with a capital raising.
In the March 2015 quarterly the company said that it increased its efforts to identify opportunities in the therapeutic space to add to its biotechnology portfolio.
Alongside this, the company is evaluating alternative ways to progress the development of its Oraline ® family of workplace saliva drug testing products.
The ASX has granted SBN a trading halt, with its shares placed in pre-open.
The halt will last until the earlier of the opening of trade on Wednesday 13th May 2015, or when an announcement is made to the market.
